Inotuzumab Ozogamicin: Uses, Treatment, and Side Effects

Inotuzumab ozogamicin is a targeted cancer therapy approved for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), a fast-moving blood cancer that has either come back after treatment or stopped responding to it. It works by delivering a potent cell-killing molecule directly to leukemia cells, and in the pivotal clinical trial, roughly four out of five patients who received it achieved remission, compared to about three in ten on standard chemotherapy. That dramatic difference in response rates is what drove its approval, but the drug also carries serious risks, particularly liver damage, that anyone considering treatment needs to understand.

What It Treats

The U.S. Food and Drug Administration approved inotuzumab ozogamicin (sold under the brand name Besponsa) for adults whose B-cell precursor ALL has relapsed or proven refractory to earlier treatment. B-cell ALL is a cancer of immature white blood cells, and when it fails to respond to standard chemotherapy or returns after an initial remission, options narrow quickly. Inotuzumab ozogamicin fills that gap by targeting a protein called CD22, which sits on the surface of most B-cell ALL cells.¹

Although the formal approval is limited to adults, the drug is increasingly used off-label in children and adolescents with relapsed or refractory B-cell ALL. A Children’s Oncology Group phase II trial found a combined complete remission rate of about 58% after one cycle in a heavily pretreated pediatric population, with two-thirds of those responders clearing their disease down to undetectable levels.² A separate retrospective study in pediatric patients reported complete remission in about two-thirds of those with overt bone marrow disease, with the majority of responders also achieving negative minimal residual disease.³ The drug has also shown promise in children and young adults whose disease progressed after CAR-T cell therapy targeting CD19, a scenario in which treatment options are particularly limited.⁴

How It Works

Inotuzumab ozogamicin belongs to a class of drugs called antibody-drug conjugates. Think of it as a guided missile: the antibody portion recognizes and latches onto CD22 on the surface of leukemia cells, and the whole package gets pulled inside the cell. Once internalized, the toxic payload, a substance called calicheamicin, is released. Calicheamicin damages DNA by wedging into its structure and snapping both strands, which triggers the cell to self-destruct.⁵

The specificity of this approach is what distinguishes it from conventional chemotherapy. Standard chemo poisons rapidly dividing cells indiscriminately, hitting both cancer and healthy tissue. Inotuzumab ozogamicin, by contrast, is engineered to home in on cells displaying CD22. Once the antibody binds and the complex is internalized, the calicheamicin payload is released inside the cell, binds to DNA, and triggers cell death. Preclinical modeling has mapped each step of this process, from the drug circulating in the bloodstream, to diffusing into tumor tissue, to binding CD22, entering the cell, and releasing calicheamicin to find its DNA target.⁶ That selectivity is genuine but imperfect: the payload can still cause collateral damage, particularly to the liver, as discussed below.

How Well It Works in Clinical Trials

The landmark study behind inotuzumab ozogamicin’s approval was INO-VATE, a randomized phase III trial that compared the drug head-to-head with standard salvage chemotherapy in adults with relapsed or refractory ALL. In that trial, about 81% of patients in the inotuzumab ozogamicin group achieved complete remission, versus roughly 29% on standard therapy.⁷ The final long-term analysis of the same trial confirmed these numbers, reporting a combined complete remission rate of about 74% with inotuzumab ozogamicin versus 31% with standard care.⁸

Beyond just achieving remission, the depth of response mattered. Among patients who entered remission on inotuzumab ozogamicin, about 78% had their disease reduced below the threshold for minimal residual disease, the tiny traces of leukemia detectable only by sensitive lab tests. In the standard therapy group, only about 28% reached that depth.⁷ Clearing residual disease matters because patients who achieved that milestone had a median overall survival of about 14 months, compared with roughly 7 months for those who still had detectable disease after treatment.⁹

Disease burden at the start of treatment also influenced outcomes. A subgroup analysis of INO-VATE found that inotuzumab ozogamicin improved progression-free survival regardless of whether patients started with low, moderate, or high levels of leukemia in their marrow, but the absolute outlook was better for those who began with less disease. The probability of remaining progression-free at two years was roughly 20% for patients with low disease burden, compared to about 7% for those with high burden.¹⁰

Treatment Schedule and Dosing

Inotuzumab ozogamicin is given as an intravenous infusion, typically in cycles that last three to four weeks. The approved dosing schedule splits each cycle into three smaller doses rather than one large infusion. This fractionated approach evolved from early clinical experience: initial trials used a single larger dose of 1.3 to 1.8 mg/m² every three to four weeks, but investigators later switched to a weekly schedule (a larger dose on day 1 and smaller doses on days 8 and 15) after lab studies suggested that more frequent exposure was more effective at killing leukemia cells.¹¹ The weekly divided schedule also appeared to reduce peak toxicity compared with the single large dose.

Most patients receive two to three cycles, and treatment duration depends on response. In a Korean real-world surveillance study of 107 patients, the median number of cycles was two, with a median treatment duration of about 43 days.¹² The prescribing information recommends limiting treatment to a maximum of six cycles, in part because longer exposure raises the risk of liver toxicity.

Bridging to Stem Cell Transplant

For many patients with relapsed or refractory ALL, the ultimate goal of treatment is not just remission but getting well enough to undergo a stem cell transplant, which offers the best shot at long-term survival. Inotuzumab ozogamicin is often used specifically as a “bridge” to transplant, inducing remission so that patients become eligible for the procedure. In a multicenter real-world study, about 37% of patients treated with inotuzumab ozogamicin went on to receive a transplant.¹³

Patients who achieved remission with inotuzumab ozogamicin and proceeded directly to their first transplant without additional chemotherapy fared best, with a two-year post-transplant survival probability of about 51%.¹⁴ This strategy has also been used in pediatric cases, including children whose disease relapsed after CAR-T cell therapy; case reports describe two to three cycles of inotuzumab ozogamicin successfully bridging these heavily pretreated patients to transplant.¹⁵

Major Side Effects

The side effects of inotuzumab ozogamicin fall into two broad categories: blood count problems (myelosuppression) and liver damage. Both are direct consequences of the calicheamicin payload hitting cells beyond the intended CD22-positive leukemia targets.

Myelosuppression

Drops in blood counts are the most common side effects. In the INO-VATE trial, low platelet counts (thrombocytopenia) occurred in about half of patients, with severe drops in roughly a quarter. Prolonged low platelets lasting beyond six weeks were common. Low white blood cell counts (neutropenia) affected a similar proportion, and about a quarter of patients developed fever with neutropenia, a sign of infection risk. Infections were reported in nearly half of patients, though fatal infections occurred in about 5%. Bleeding events happened in about a third of patients, most often nosebleeds; severe hemorrhage was uncommon, affecting around 5%.¹⁶ Blood counts are monitored before every dose, and treatment may be paused if counts drop too low. Preventive antibiotics or antifungals are often prescribed to reduce infection risk during treatment.

Liver Toxicity and Sinusoidal Obstruction Syndrome

The most feared complication is a form of liver damage called sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD). In this condition, tiny blood vessels inside the liver become blocked, leading to liver swelling, fluid retention, weight gain, and jaundice. It can progress to multi-organ failure and death. This risk is significantly elevated when patients go on to receive a stem cell transplant after inotuzumab ozogamicin.¹⁷

The rates of this complication vary across studies, which partly reflects differences in how many patients went on to transplant and how closely they were monitored. In the multicenter real-world Italian study, about 11% of patients developed VOD/SOS.¹³ In the Korean post-marketing surveillance, the rate was lower at about 3%.¹² In pediatric cohorts, the rate after transplant was strikingly high: one study reported SOS in over half of children who received a transplant after inotuzumab ozogamicin,³ while the Children’s Oncology Group trial found it in about 29% of transplanted patients.²

Risk factors for SOS/VOD include older age, prior liver disease, previous transplant, and the use of certain conditioning regimens before transplant that are particularly hard on the liver. Limiting the number of inotuzumab ozogamicin cycles before transplant and choosing gentler conditioning regimens can help reduce, but not eliminate, this risk.¹⁸ One small study evaluated ursodiol (a bile acid medication) as a preventive measure, finding that the rate of liver toxicity was numerically lower in patients who took ursodiol (14% versus 43% without it), but the difference was not statistically significant after adjusting for other factors.¹⁹ So ursodiol is sometimes used in practice, but firm evidence that it prevents liver problems is still lacking.

How It Compares to Other Targeted Therapies

The main alternative targeted therapy for relapsed or refractory ALL is blinatumomab, a bispecific antibody that redirects a patient’s own immune cells to attack leukemia cells bearing CD19. No head-to-head randomized trial has compared the two drugs directly, so researchers have tried indirect comparisons, adjusting for differences between the separate clinical trials of each drug.

The results depend on who ran the analysis. One matching-adjusted comparison found that blinatumomab had a similar complete remission rate and a possible survival advantage over inotuzumab ozogamicin in patients who had received no more than one prior salvage regimen.²⁰ A different set of indirect comparisons, using multiple statistical methods, found significantly higher remission rates and transplant rates with inotuzumab ozogamicin, with no clear difference in overall survival between the two.²¹ In practice, the choice between them often depends on which antigen the patient’s leukemia expresses (CD22 for inotuzumab ozogamicin, CD19 for blinatumomab), prior treatment history, liver function, and whether the goal is to bridge quickly to transplant.

Combination Approaches and Frontline Use

An active area of research is whether inotuzumab ozogamicin can work better in combination with other drugs, or earlier in the course of disease, rather than being reserved for relapsed cases. One notable study from MD Anderson Cancer Center compared a low-intensity chemotherapy backbone combined with inotuzumab ozogamicin (with or without blinatumomab) against standard intensive chemotherapy in older adults newly diagnosed with ALL. The combination approach produced higher response rates (98% versus 88%), fewer early deaths, and substantially better three-year event-free survival (64% versus 34%) and overall survival (63% versus 34%).²² These results are striking because older patients tolerate intensive chemotherapy poorly, and the combination allowed a gentler backbone while actually improving outcomes.

This study was not randomized in the traditional sense — it used propensity score matching to compare the two groups — so the evidence is not as strong as it would be from a blinded trial. Still, the magnitude of the benefit has spurred randomized trials investigating inotuzumab ozogamicin in frontline settings for both older and younger adults, with results expected in the coming years.

When Treatment Stops Working

Like most targeted therapies, inotuzumab ozogamicin does not work permanently for everyone. Some patients never respond, and among those who do, relapse is common. Researchers have begun to identify the genetic reasons. A genomic study of post-treatment samples found that about 11% of patients who relapsed after inotuzumab ozogamicin had acquired mutations in the CD22 gene itself. These mutations changed or disrupted the part of CD22 that the antibody binds to, allowing leukemia cells to effectively dodge the drug. Interestingly, these mutations showed up only in patients who initially responded and then relapsed, not in those who never responded at all, suggesting that primary resistance involves different mechanisms.²³

Understanding these resistance mechanisms is important because it opens the door to sequencing therapies strategically. A patient whose leukemia develops CD22 mutations, for instance, might still respond to a CD19-directed therapy like blinatumomab or CD19-targeted CAR-T cells, since those drugs use an entirely different target.

Real-World Performance Outside Clinical Trials

Clinical trial populations are carefully selected, which always raises the question of whether a drug performs as well in everyday practice. Real-world data from multiple countries suggests that inotuzumab ozogamicin works, though outcomes in routine care are modestly less favorable than in trials, as is typical for most cancer drugs.

A multicenter Italian study of 73 patients, many of whom had received three or more prior lines of therapy (including more than half who had already received blinatumomab), reported an overall response rate of 74% and a complete remission rate of about 70%. Median overall survival was roughly 8 months, with about 21% of patients alive at three years.¹³ The Korean post-marketing surveillance study, which included 107 patients, found a median progression-free survival of about 3.6 months and overall survival of about 10 months. The most common side effects mirrored trial data: blood count drops, infections, and gastrointestinal problems.¹²

These numbers may seem modest in absolute terms. Median survivals measured in months, not years, reflect the reality that relapsed or refractory ALL is an aggressive disease. What the data consistently shows is that inotuzumab ozogamicin produces significantly higher remission rates than salvage chemotherapy alone, and those remissions can serve as a crucial window for patients to reach transplant, which remains the best route to long-term survival.

Cost-Effectiveness

Targeted cancer therapies are expensive, and inotuzumab ozogamicin is no exception. A health economic analysis comparing it to standard chemotherapy in Scandinavian settings estimated the incremental cost per quality-adjusted life year gained at roughly €16,000 to €44,000, depending on the country and the assumptions used. When applying the more conservative preferred assumptions of the Swedish and Norwegian health technology assessment bodies, estimates rose to about €59,000 to €77,000 per quality-adjusted life year.²⁴ In most European health systems, these figures fall within or near the range considered acceptable for cancer treatments, though the exact thresholds vary by country. Access and reimbursement decisions differ globally, and patients in some regions may face insurance coverage hurdles even though the drug has regulatory approval.